Sacramento News-Online

Glaucoma Therapeutic Pipeline Analysis, 2022 | Insights into the Latest FDA and EMA Approvals, Clinical Trials, and Treatment Algorithm | Santen/UBE (OMLONTI), Qlaris Bio (QLS-101), Nicox (NCX 470)

 Breaking News
  • No posts were found

Glaucoma Therapeutic Pipeline Analysis, 2022 | Insights into the Latest FDA and EMA Approvals, Clinical Trials, and Treatment Algorithm | Santen/UBE (OMLONTI), Qlaris Bio (QLS-101), Nicox (NCX 470)

September 30
19:16 2022
Glaucoma Therapeutic Pipeline Analysis, 2022 | Insights into the Latest FDA and EMA Approvals, Clinical Trials, and Treatment Algorithm | Santen/UBE (OMLONTI), Qlaris Bio (QLS-101), Nicox (NCX 470)
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 70+ key pharma and biotech companies are working on 70+ pipeline drugs in the Glaucoma therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Glaucoma Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Glaucoma Market. 

The Glaucoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Glaucoma Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of Glaucoma and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glaucoma Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Glaucoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

DelveInsight’s Report covers around 70+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Latest Clinical and Commercial Developments in the Glaucoma Therapeutics Market

On September 26, 2022, Santen Inc. and UBE Corporation (UBE) announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension.

Learn How the Ongoing Clinical & Commercial Activities will Affect the Glaucoma Therapeutic Segment:

https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight

Glaucoma Therapeutics Landscape

In general, glaucoma cannot be cured, but it can be controlled. Eye drops, pills, laser procedures, and surgical operations are used to prevent or slow further damage from occurring. With any type of glaucoma, regular eye examinations are very important to detect progression and prevent vision loss.

There are approx. 70+ key companies which are developing therapies for Glaucoma. Currently, Nicox has its Glaucoma drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Glaucoma Therapeutics Market include:

Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, AbbVie, JeniVision, Inc., Ocular Therapeutix, Annexon, Inc., Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Kowa, D. Western Therapeutics Institute, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, and several others.

Glaucoma Drugs Covered in the report include:

• QLS-101: Qlaris Bio, Inc. 

• NCX 470: Nicox

And many more 

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Glaucoma Current Treatment Patterns

4. Glaucoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Glaucoma Late Stage Products (Phase-III)

7. Glaucoma Mid-Stage Products (Phase-II)

8. Glaucoma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Glaucoma Discontinued Products

13. Glaucoma Product Profiles

14. Key Companies in the Glaucoma Market

15. Key Products in the Glaucoma Therapeutics Segment

16. Dormant and Discontinued Products

17. Glaucoma Unmet Needs

18. Glaucoma Future Perspectives

19. Glaucoma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Hyperglycemia Market

“Hyperglycemia Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Hyperglycemia Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/